- The product developed by Pfizer and BioNTech is 90% effective, the producer says. The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020.
- Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.
- After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the Data Monitoring Committee performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose.
- Pfizer says there are no serious side effects. If key indicators are safe, the world may have a tool to tackle the pandemic in a week.
- The European Commission has already agreed to sign an agreement with the developers on the purchase of 300 million doses of the coronavirus vaccine.
Zelensky asks Merkel to assist in allocating COVID-19 vaccine to Ukraine

The parties agreed to further coordinate efforts to overcome the consequences of the pandemic.
President of Ukraine Volodymyr Zelensky on November 10 had a phone call with Germany's Chancellor Angela Merkel during which he asked the German leader to assist in supplying a U.S.-German-developed COVID-19 vaccine to Ukraine.
"We welcome the breakthrough achieved by the German company BioNTech together with the American company Pfizer in the development of a coronavirus vaccine. This is very encouraging news. I would like to ask for your assistance in taking into account the interests of Ukraine when planning the supply of COVID-19 vaccine," Zelensky said, according to the press service of the Ukrainian President's Office.
Pfizer vaccine
Latest news
Latest newsRomania Faces Political Deadlock: Nicusor Dan Moves to Form a New Government
01.Sep.2026
Pashinyan Meets Aliyev in Bishkek: Armenia and Azerbaijan Prepare for a New Stage in the Peace Process
01.Sep.2026
Ukraine Plans to Present Allies with a New War Strategy and Seek Early EU Funding
31.Aug.2026
The Mecca Pact — Protection or a Trap for Turkiye?
30.Aug.2026
Tigran Khzmalyan: Armenia must make a Decisive Choice in Favor of Europe
30.Aug.2026
Bulgaria to Strengthen Its Black Sea Fleet: Sofia to Receive Seven Minehunter Vessels
29.Aug.2026
Russia Intensifies Strikes on Ukraine’s Infrastructure, Targeting Warehouses and Logistics Hubs
28.Aug.2026
A New Economic Framework for Central Asia and the Caucasus: The Role of Azerbaijan and Uzbekistan
28.Aug.2026
Moscow Warns London: Russia Considers Strikes on British Military Targets
27.Aug.2026
Kazakhstan Launches a New Economic Strategy: GDP Growth, Investment and Pension Reform
27.Aug.2026
CIA Director Visits Moscow: Trump Hopes for Results
26.Aug.2026
Former Ukrainian Defense Minister Warns of Risk of Gradual Defeat in War with Russia
25.Aug.2026
Putin Authorizes Temporary State Management of Critical Infrastructure Vulnerable to Drone Attacks
24.Aug.2026
The United States Rapidly Expands Missile Production: Pentagon Accelerates Output of Tomahawks and Other Critical Weapons
24.Aug.2026
Record Supplies: Armenia Boosts Fish Exports to Georgia
23.Aug.2026

02 Sep 2026


